CCL Pakistan Transformation Plan Cambodia.pptx

How to transform the Business for CCL Pakistan for Cambodia into a Viable Profitable Scenario

1. Transformation Plan Cambodia 2024-2025 #OneTeamOneDream

2. Overview Cambodia

3. Cambodia & Demographics Official Name : Kingdom of Cambodia Neighbour Countries: Vietnam, Thailand, Laos. Area : 181,000 km² Land Area : 176,515.00 km² Water Area : 4,520.00 km² Capital City : Phnom Penh - Also Largest city Population 2,281,198 25 Provinces Analysis of Population Current population 17,712,173 Population Rank 70th Male population 49% 8,670,414 Female population 51% 9,041,759 Population Growth Rate 1,41% Literacy 72% Life Expectancy Male 60.7 Life Expectancy Female 65.1 Religion in Cambodia Buddhisim 96.90% Muslim 2.00% Age Structure Under 15 Years 32.20% 15-64 Years 64.10% 65 + 3.40% Median Age 24.0 Years

4. Provinces Population Wise S.No. Name Capital (seat) Area (km) Population (2019) Density 1 Phnom Penh (Autonomous municipality) Doun Penh Section 679 2281951 3136 2 Kandal Ta Khmau Municipality 3179 1201581 376 3 Takéo Doun Kaev Municipality 3563 900914 252 4 Prey Veng Prey Veng Municipality 4883 1057720 217 5 Kampong Cham Kampong Cham Municipality 4549 899791 197 6 Svay Rieng Svay Rieng Municipality 2966 525497 177 7 Preah Sihanouk Sihanoukville Municipality 1938 310072 156 8 Tboung Khmum Suong Municipality 5250 776841 148 9 Banteay Meanchey Serei Saophoan Municipality 6679 861883 129 10 Kampong Speu Chbar Mon Municipality 7017 877523 124 11 Kep Kep Municipality 336 42665 124 12 Kampot Kampot Municipality 4873 593829 122 13 Siem Reap Siem Reap Municipality 10299 1014234 98 14 Kampong Chhnang Kampong Chhnang Municipality 5521 527027 95 15 Pailin Pailin Municipality 803 75112 89 16 Battambang Battambang Municipality 11702 997169 84 17 Kampong Thom Steung Saen Municipality 13814 681549 49 18 Oddar Meanchey Samraong Municipality 6158 276038 42 19 Kratié Kratié Municipality 11094 374755 34 20 Pursat Pursat Municipality 12692 419752 32 21 Ratanakiri Banlung Municipality 10782 217453 19 22 Preah Vihear Tbaeng Meanchey Municipality 13788 254827 18 23 Stung Treng Stung Treng Municipality 11092 165713 14 24 Koh Kong Khemarak Phoumin Municipality 10090 125902 12 25 Mondulkiri Senmonorom Municipality 14288 92213 6

5. Cambodia Macro Economics GDP $32.291 billion GDP Growth 5% in 2023 Inflation 4% in 2023 GDP per capita USD $1,917 in 2023, International trade $46.82 billion in 2023 Total exports USD $22.64 billion in 2023 The tourism, garment, construction, real estate, and agriculture sectors accounted for the bulk of growth. 700,000 people garment and footwear sector. 500,000 Cambodians in the tourism 200,000 people in construction.

6. Market Analysis

7. Market Analysis Revenue Pharmaceuticals market is projected to reach US$ 177.00m in 2024. CAGR 2024-28 5.47% reulting in Market Volume US $ 219.00 M by 2028 In 2021,3,312 pharmacies, 5000 Drs, 590 drug importer/exporter, 15 manufacturing institutions. Oncology Drugs with a projected market volume of US$30.00m in 2024 Diabetese is fastest Growing Therapeutic class.

8. Major Pharmaceutical Import Countries

9. Major Pharmaceutical Companies

10. T op H ospitals a n d P r i v a te C l i nics in C a mb o d ia 9 Go v e r nm e nt H o s p i t a l i n P h n o m P e n h C i t y , 4 i n P r o v i nc e & 5 p r i v a t e ho s p i t a l .

11. Hospitals and Clinic in Province

12. Major Therapeutic Class Cambodia Oncology Drugs Anti Coagulants ------ Noclot Anti Rheumatic ------ Dorsiflex & Vitaxon Vitamins & Minerals - Once A Day Cough & Cold --- Pulmonol Syp Anti Diabetics - Sita & Orinase Anti Hypertensive - Normozide Therapeutic Class CAGR (24-28) 2024 - Value US$ Pharma Market Size 5.47% 177 M V&M 6.75% 49.08M Anti-Coagulants 8.36% 6.35M Cold & Cough 8.12% 43.80M Anti Rheumatic 1.16% 4.22M Anti- Diabetic 6.18% 26.59M Anti Hypertensive 0.26% 3.07M Anti Cancer 30.0M

13. CCL in Cambodia CCL has been present in Cambodia since 2002 Highest sales in 2015-2018-2019

14. Cambodia Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 Jan-24 Feb-24 Mar-24 Apr-24 May-24 Jun-24 TOTAL Sales - Secondary 69,948 69,948 71,232 77,770 78,123 79,435 82,285 82,477 83,780 84,378 86,730 87,957 954,062 Direct sales force 15,179 13,879 11,367 19,697 14,397 13,697 19,497 15,697 14,397 15,697 13,697 21,697 188,902 DSF %age 22% 20% 16% 25% 18% 17% 24% 19% 17% 19% 16% 25% 20% Marketing Activities 22,094 22,094 22,402 23,971 24,056 24,371 26,883 26,929 27,242 27,386 27,950 28,245 303,625 Marketing Activities %age 32% 32% 31% 31% 31% 31% 33% 33% 33% 32% 32% 32% 32% Direct Field Force Salary 3,760 3,760 3,948 5,748 5,748 5,748 5,748 5,748 5,748 5,748 5,748 5,748 63,200 Allowances 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 60,000 Incentive 650 650 650 1,030 1,030 1,030 1,030 1,030 1,030 1,030 1,030 1,030 11,220 Bonus 313 313 313 463 463 463 463 463 463 463 463 463 5,110 HO Cost 1,456 1,456 1,456 1,456 1,456 1,456 1,456 1,456 1,456 1,456 1,456 1,456 17,472 Travel - BH 2,000 700 - 6,000 700 - 3,800 - 700 2,000 - - 15,900 Trainings 2,000 2,000 4,000 Team Meeting 2,000 2,000 4,000 Ach. Conference 8,000 8,000 15,179 13,879 11,367 19,697 14,397 13,697 19,497 15,697 14,397 15,697 13,697 21,697 188,902 Marketing Activities Direct Sponsorship 3,657 3,657 3,657 3,657 3,657 3,657 5,485 5,485 5,485 5,485 5,485 5,485 54,850 CME-INTERNATIONAL - - - - - - - - - - - - - CME-LOCAL 400 400 400 400 400 400 400 400 400 400 400 400 4,800 Marketing Campaign 1,150 1,150 1,150 1,150 1,150 1,150 1,150 1,150 1,150 1,150 1,150 1,150 13,800 Promotional Giveaway 100 100 100 100 100 100 100 100 100 100 100 100 1,200 Product Literature - - - - - - - - - - - - - Clinical Research - - - - - - - - - - - - - Discounts 16,787 16,787 17,096 18,665 18,749 19,064 19,748 19,794 20,107 20,251 20,815 21,110 228,975 22,094 22,094 22,402 23,971 24,056 24,371 26,883 26,929 27,242 27,386 27,950 28,245 303,625

15. BUDGET ROLL-UP SECONDARY SALES TARGET 932,000 OPERATIONAL 11,100 1.19% MONTHLY AVERAGE 77,667 PROMOS 333,549.70 35.79% COGS 465,999.87 50.00% OPERATIONAL TOTAL COST 810,650 86.98% SALARIES INCENTIVE TRAVEL MONTHLY Gross Months GROSS PROFIT 121,350 13.02% Phavy Phoeun 1,350 200 750 1,350 12 Tor Chintra 560 90 500 560 12 Pen Srey Oun 550 90 500 550 12 Hy Sochea 450 90 500 450 12 Nay Rotha 450 90 500 450 12 Chhun Vansanti 400 90 500 400 12 OTC Team Leader 1,000 200 750 1,000 9 Jaudat quarterly travel New Med Rep (OTC) 400 90 500 400 9 CL quarterly travel New Med Rep (OTC) 400 90 500 400 9 President yearly Salary 5,560 1,030 5,000 5,560 Travel 11,100 13th Salary Admin 15,000 13th Salary 5,560 37,220 PROMOS RATE FY AMOUNT MONTHLY DETAILS Discounts 244,329.70 20,360.81 Trading Terms Sponsorships 69,420.00 5,785.00 KOL Investment Marketing Activities 19,800.00 1,650.00 TOTAL FY 23-24 333,549.70 26,145.81 COGS RATE FY AMOUNT MONTHLY DETAILS CIF 33% 307,559.92 25,629.99 COGS +Transport DISTRIBUTOR MARGIN 14% 130,479.96 10,873.33 Straight Debit OTHER FEES 3% 27,959.99 2,330.00 Office + Registrations TOTAL FY 23-24 465,999.87 38,833.32 Marketing Budget should be provided to FF TO achieve the target.

16. Previous Years Ach Vs Budget 2023-24 Total Achievement 2020-21 Total Achievement 2021-22 Total Achievement 2022-23 Budget 2023-24 483,645 436,004 462,757 954062

17. Target Vs Sales Jul- Dec 2023

18. 2015-2023 583624 533051 530591 604104 561793 519204 413855 418346 503205

19. Product 2015 Units 2016 Units 2017 Units 2018 Units 2019 Units 2020 Units 2021 Units 2022 Units 2023 Units CCL-C00242 - CRESTAT 5MG 10'S-B/10'S 2,722 1,869 1,148 1,098 1,064 685 295 20 CCL-C00243 - CRESTAT 10MG 10'S-B/10'S 4,084 2,630 2,225 2,640 1,770 1,763 1,585 1,285 629 CCL-C00244 - CRESTAT 20MG 10'S-B/10'S 2,818 2,717 3,111 2,862 1,368 1,146 578 310 310 CCL-C00245 - CEF-OD SUSP. 100MG/5ML-30ML-BOT/30ML 12,873 15,130 14,152 17,681 23,966 19,040 6,382 30,106 19,319 CCL-C00246 - CEF-OD SUSP. 200MG/5ML-30ML-BOT/30ML 3,450 5,520 8,116 8,078 9,970 3,865 1,100 6,585 4,600 CCL-C00247 - CEF-OD TABLET 200MG 10'S-B/10'S 3,405 4,820 4,381 7,491 6,930 2,135 CCL-C00248 - CEF-OD CAPSULE 400MG 5'S-B/5'S 1,445 2,701 5,045 3,911 3,444 2,700 390 CCL-D00147 - DORSIFLEX 200MG 20'S-B/20'S 10,800 10,395 8,855 10,275 7,062 4,245 3,338 1,206 1,161 CCL-D00148 - DILCOZYME SYRUP 120ML-BOT/120ML 7,182 6,767 8,198 8,697 7,548 6,539 3,893 5,408 2,248 CCL-E00142 - ESPRA 40MG 14'S-B/14'S 10,840 9,854 6,943 7,548 4,997 4,976 3,793 3,539 2,932 CCL-G00165 - GABLIN CAPSULE 150MG 14'S-B/14'S 4,191 1,868 2,276 2,256 2,367 1,667 1,568 1,546 1,090 CCL-G00166 - GABLIN CAPSULE 75MG 14'S-B/14'S 7,837 6,912 8,891 13,862 14,193 15,889 15,902 20,251 7,416 CCL-L00153 - LEVOCIL 250MG 10'S-B/10'S 2,227 1,292 930 1,672 2,673 1,906 760 1,383 1,573 CCL-L00154 - LEVOCIL 500MG 10'S-B/10'S 1,527 1,435 1,426 1,161 1,015 688 171 481 125 CCL-L00155 - LEVOCIL INFUSION 500MG/100ML-BOT/100ML 420 2,660 3,545 3,139 1,858 1,200 340 100 CCL-M00142 - MOLOX 400MG 5'S-B/5'S 6,889 5,003 3,980 5,829 3,855 2,418 712 340 170 CCL-M00145 - MOLOX IV INFUSION 400MG/250ML-BOT/250ML 1,599 904 1,660 1,096 845 559 120 CCL-M00143 - MONTELUK 5MG 10'S-B/10'S 2,585 2,280 1,770 1,477 1,289 450 800 1,334 560 CCL-M00144 - MONTELUK 10MG 10'S-B/10'S 2,806 2,133 3,659 5,979 3,333 3,100 2,440 752 255 CCL-M00146 - MONTELUK 4MG 10'S-B/10'S 1,426 1,515 1,790 1,837 1,506 678 93 470

20. Product 2015 Units 2016 Units 2017 Units 2018 Units 2019 Units 2020 Units 2021 Units 2022 Units 2023 Units CCL-N00163 - NOCLOT 75MG 20'S-B/20'S 2,426 2,312 1,583 1,616 1,215 1,130 1,187 870 953 CCL-N00165 - NORMOZIDE 10'S-B/10'S 2,292 3,236 2,673 4,828 6,578 2,719 2,160 1,652 1,160 CCL-N00166 - NEOKLAR 250MG 10'S-B/10'S 5,680 3,312 3,370 3,402 2,118 CCL-N00167 - NEOKLAR 500MG 10'S-B/10'S 1,775 1,847 1,170 497 615 924 234 81 CCL-O00159 - ORINASE 2MG 20'S-B/20'S 4,761 5,295 4,844 4,243 4,010 4,934 6,158 6,006 3,991 CCL-O005785 - ORINASE MET 1 3X10S-B/3X10'S 965 2,436 1,945 3,007 2,880 4,251 4,873 5,745 5,446 CCL-O005805 - ORINASE MET 2 3X10S-B/3X10'S 2,615 3,582 6,230 9,957 13,547 18,834 24,461 33,895 36,321 CCL-O006325 - ONCE A DAY AX 3X10S-B/3X10'S 2,217 2,427 3,134 1,952 1,305 206 1,021 CCL-O010525 - ONCE A DAY 3X10S-B/3X10'S 691 1,382 166 446 CCL-P004991 - PROSTATIN 10MG TABLET 10S-B/10'S 4,347 3,190 2,781 2,966 3,316 3,045 2,914 1,270 CCL-P005525 - PRO-STATIN 20MG 1X10S-B/1X10'S 2,100 760 1,523 1,915 2,291 1,866 1,994 1,780 1,301 CCL-P007345 - PULMONOL SYRUP 120ML-BOT/120ML 3,902 6,565 8,228 7,198 5,728 6,932 10,676 11,936 CCL-S004989 - SITA 100MG TABLET 14S-B/14'S 4,869 4,212 2,440 2,591 2,091 2,495 2,361 2,598 2,724 CCL-S004992 - SITA 50MG TABLET 14S-B/14'S 4,285 2,431 2,036 4,582 4,070 5,011 6,008 5,932 7,384 CCL-S005825 - SITA MET 50-500MG 2X7S-B/2X7'S 1,050 2,504 2,591 5,152 4,595 6,617 10,723 16,828 21,159 CCL-S005826 - SITA MET 50-1000MG 2X7S-B/2X7'S 270 2,100 1,476 2,591 4,290 7,240 8,696 9,071 11,153 CCL-V00136 - VITAXON 500MCG 3X10'S-B/30'S 18,624 14,743 14,972 14,730 15,025 12,130 7,096 9,441 8,398 CCL-V00137 - VITAXON 500MCG INJ.10AM.-B/10AMP 2,231 1,944 2,264 2,636 2,786 2,225 857 2,019 1,280 Sum 153,737 145,263 151,350 185,634 181,162 157,738 133,801 184,527 156,140

21. Year 2015 2016 2017 2018 2019 2020 2021 2022 2023 SKUs 41 39 45 59 56 59 56 43 30 Year 2015 2016 2017 2018 2019 2020 2021 2022 2023 DISCOUNT % 0% 7% 10% 10% 9% 8% 16% 28% 33% SKUs & Discount 2015 - 2023

22. Key Challenges in Business Cambodia Inconsistent/ Irrational Team Size Gradual Wipe Off Acute Care Portfolio MOQ Discount Dependancy

23. INTERNAL Fertile Market / Growing Economy Better Purchase Power Market realted Product Portfolio Increasing National Social Secuity Increasing Competiton Delay Approval/ Regulations Govt encourage Local Manufacturer O Weak Market Penetration Rare Marketing Activities Irrational FF Size/Inconsistent High Discount % /Dependancy Very Low Customer Base Product Self Life 2 Years S W 21 Years Presence Best Distributorion Network Established Efficacy T SWOT ANALYSIS EXTERNAL

24. Team Size 2015- 2023 Head Count 2015 2016 2017 2018 2019 2020 2021 2022 2023 Teams 2 2 2 2 2 3 3 2 1 Managers 2 2 2 2 2 3 3 2 1 Medical Reps 6 6 8 9 10 16 8 6 5 Sales Manager 1 1 - Total Team Size 8 8 10 1 1 12 20 13 8 6

25. Existing Team Structure – Cambodia Mr. Pheun Phavy Field Manager DOJ 13-10-14 Mr. Hy Sok Chea Medical Representative DOJ 4-12-22 Khmer Souvitte Hospital Svay Reng, Prey Veng, Sin Dalim Medical Representative 2-1-2024 Hope Centre Kartie, Stueng Reng Mr. Tor Chentra Sr Medical Representative DOJ 2-11-2010 National Pediatric Hospital Battambang & Banteay Meanchey MS Pen Sreyoun Sr Medical Representative DOJ 8-6-2013 Calmette Hospital SIEM REAP & Kampong Thom Mr. Ny Rotha Sr Medical Representative DOJ 1-10-2022 Kossmak Hospital Kampot, Takeo, Kampong Champ Mr. Y Sothea Field Manager DOJ 17-1-24 9 YEARS 13 YEARS 10 YEARS

26. Right Sizing FF & Portfolio

27. 1 Prostatin 10mg & 20mg 1 Dilcozyme Digestive Enzymes 2 Crestat 5mg/10/20mg 2 Cef-Od Cefixime 100mg/200mg 3 Normozide 50+12.5mg 3 Pulmonol Expectorant Syp 4 Noclot 75mg 4 Dorsiflex Celcoxib 200mg 5 Gablin Pregablin 75mg/150mg 5 Molox Moxifloxacin 400mg 6 Orinase 2mg 6 Espra Esomeprazole 40mg 7 Orinase Met 1mg & 2mg 7 Once A Day Max Multivitamin 8 Vitaxon 50mcg Tab & Inj 8 Montelux 4mg/5mg/10mg 9 Sita 50/100mg 9 Neo-Klar 250mg/500mg 10 Sita-Met 50+500mg & 50+1000mg 10 Levocil 250mg/500mg 1 Sita-DM Natural Glycemic Control 1 Alkid Cotlix Natural Colic Relief for Kids Metabolism Care Primary/ Acute Care Team I Team II Suggested -2024 QI-5, Q2-8, Q3-8 & Q4 10

28. Restoration of Acute Care Portfolio

29. Acute Care Portfolio Value 2017 Onward Product Name 2017 2018 2019 2020 2021 2022 2023 Amount Amount Amount Amount Amount Amount Amount CEF-OD CAPSULE 400MG 5'S 16,043 12,437 10,952 8,586 1,240 - - CEF-OD TABLET 200MG 10'S 17,918 30,638 28,344 8,732 - - -   33,961 43,075 39,296 17,318 1,240 - - CRESTAT 5MG 10'S 1,825 1,746 1,692 1,089 469 32 - EUFACLOR 125MG 12S 1,183   - 3,083 2,384 1,452 - EUFACLOR 250MG 1X12S 538   - 1,646 535 - -   3,546 1,746 1,692 5,818 3,388 1,484 - LEVOCIL 250MG 10'S 3,534 6,354 10,157 7,243 2,888 5,255 5,977 LEVOCIL 500MG 10'S 9,340 7,605 6,648 4,506 1,120 3,151 819 LEVOCIL INFUSION 500MG/100ML 9,922 13,223 11,708 6,930 4,476 1,268 373   22,796 27,181 28,514 18,680 8,484 9,674 7,169 MOLOX 400MG 5'S 14,845 21,742 14,379 9,019 2,656 1,268 187 MOLOX IV INFUSION 400MG/250ML 9,447 17,347 11,453 8,830 5,842 1,254 - Molox Total 24,292 39,089 25,832 17,849 8,497 2,522 187   24,292 39,089 25,832 17,849 8,497 2,522 187 MONTELUK 10MG 10'S 9,989 16,323 9,099 8,463 6,661 2,053 696 MONTELUK 4MG 10'S 2,846 2,921 2,395 1,078 148 747 - MONTELUK 5MG 10'S 2,903 2,422 2,114 738 1,312 2,188 779   15,738 21,666 13,608 10,279 8,121 4,988 1,475 NEOKLAR 500MG 10'S 6,119 2,599 3,216 4,833 1,224 424 - 6,119 2,599 3,216 4,833 1,224 424 - Total 106,453 135,356 112,158 74,777 30,954 19,092 8,831

30. MOQ Challenge To be Rationalized

31. Product Minimum Order Qty Self Life Transportation Time MOH Invoice Time Saleable Time 2021 2022 2023 Dilcozyme Syrup 120ml 32000 2 Years 3 Months No Invoice Less than 6 M 15 Months 3893 5408 2248 DORSIFLEX Capsule 200mg 20's 3750 2 Years 3 Months No Invoice Less than 6 M 15 Months NORMOZIDE Tablet 10's (KH) 7100 2 Years 3 Months No Invoice Less than 6 M 15 Months Once-A-Day Maximum Tablet 30's 2400 2 Years 3 Months No Invoice Less than 6 M 15 Months PRO-STATIN Tablet 10mg 10's 20000 2 Years 3 Months No Invoice Less than 6 M 15 Months PRO-STATIN Tablet 20mg 10's 7500 2 Years 3 Months No Invoice Less than 6 M 15 Months VITAXON Injection 500mcg 10's 3500 3 Years 3 Months No Invoice Less than 6 M 18 Months 7096 9441 8398 VITAXON Tablet 500mcg 30's 16000 3 Years 3 Months No Invoice Less than 6 M 18 Months 857 2019 1280 CEF-OD CAPSULE 400MG 5'S 3000 2 Years 3 Months No Invoice Less than 6 M 15 Months CEF-OD TABLET 200MG 10'S= N.A Registration Expired 2 Years 3 Months No Invoice Less than 6 M 15 Months LEVOCIL 250MG 10'S 1000 2 Years 3 Months No Invoice Less than 6 M 15 Months LEVOCIL 500MG 10'S 1000 2 Years 3 Months No Invoice Less than 6 M 15 Months LEVOCIL INFUSION 500MG/100ML 1960 2 Years 3 Months No Invoice Less than 6 M 15 Months MOLOX 400MG 5'S= 1000 2 Years 3 Months No Invoice Less than 6 M 15 Months MOLOX IV INFUSION 400MG/250ML 785 2 Years 3 Months No Invoice Less than 6 M 15 Months NEOKLAR 500MG 10'S 1000 2 Years 3 Months No Invoice Less than 6 M 15 Months NeoKLAR 250MG 10'S 1000 2 Years 3 Months No Invoice Less than 6 M 15 Months MONTELUK 10MG 10'S 1000 2 Years 3 Months No Invoice Less than 6 M 15 Months 800 1334 560 MONTELUK 4MG 10'S= 5000 must 5000 2 Years 3 Months No Invoice Less than 6 M 15 Months 2440 752 255 MONTELUK 5MG 10'S= 5000 must 5000 2 Years 3 Months No Invoice Less than 6 M 15 Months 93 470

32. Next Three Years 2024-2027

33. Objectives for Business

34. Sales Forecast Year 2024 Jan-24 Feb-24 Mar-24 Apr-24 May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24 Nov-24 Dec-24 US $ 40,000 44,000 48,400 51,788 55,413 59,292 62,257 65,370 68,638 72,070 75,673 79,457 PKR 11,400,000 12,540,000 13,794,000 14,759,580 15,792,751 16,898,243 17,743,155 18,630,313 19,561,829 20,539,920 21,566,916 22,645,262 PKR (M) 11.40 12.54 13.79 14.76 15.79 16.90 17.74 18.63 19.56 20.54 21.57 22.65 Total 2024 Total 2023 Growth US$ 722,358 418346.45 73% Enabler I FF Size 10% Promotional Activities Budget Q-I = 5 Q-2 =8 Q-3 =8 Q-4=10 Enabler II Restoration of Acute Care Portfolio

35. Sales Forecast Year 2025 Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 US $ 83,430 87,601 91,981 96,581 101,410 106,480 111,804 117,394 123,264 129,427 135,899 142,693 PKR 23,777,525 24,966,401 26,214,721 27,525,457 28,901,730 30,346,817 31,864,158 33,457,366 35,130,234 36,886,746 38,731,083 40,667,637 PKR (M) 23.78 24.97 26.21 27.53 28.90 30.35 31.86 33.46 35.13 36.89 38.73 40.67 Total 2025 Total 2024 Growth US$ 1,327,964 722357.7863 84% Enabler I FF Size 10% Promotional Activities Budget Q-I=10 Q-2=11 Q-3=11 Q-4=12 Enabler II Restoration of Acute Care Portfolio

36. Sales Forecast Year 2026 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Jul-26 Aug-26 Sep-26 Oct-26 Nov-26 Dec-26 Total 2026 US $ 149,828 157,320 165,186 173,445 182,117 191,223 200,784 210,823 221,364 232,433 244,054 256,257 2,384,833 PKR 42,701,019 44,836,070 47,077,873 49,431,767 51,903,355 54,498,523 57,223,449 60,084,622 63,088,853 66,243,295 69,555,460 73,033,233 679,677,519 PKR(M) 42.70 44.84 47.08 49.43 51.90 54.50 57.22 60.08 63.09 66.24 69.56 73.03 Total 2026 Total 2025 Growth 2,384,833 1,327,964 80% Enabler I FF Size 10% Promotional Activities Budget Q-I =15 Q-2 =15 Q-3 =15 Q-4 =15 Enabler II Restoration of Acute Care Portfolio

37. How to Proceed /Road Map Ensure Right Sizing of Team Structure Initiate Marketing Campaigns Restoration Acute Care Portfolio

38. CCL Image Building Need to have an effective program to boost the CCL Image by Colloborating following Local Conferences. Cambodia Association of Diabetology & Endocrinology Cambodian Heart Association Medical Council of Cambodia Cambodian Society of Gastro - Hepatology Cambodian Internal Medicine Association Cambodian association of Pediatricians

39. Action Plan Action # 1 Restoration of Acute Care Portfolio. Immediate Action # 2 Increase 3 Medical Reps. March 2024 Onward Action # 3 Marketing Budget for Campaigns - 10% of Previous Month Sales Immediate Inventory Management/ MOQ Relaxation Campaigns for for Acute Care & Cardiac Care & Sita Met, Gablin for Chronic Care.

40. Campaigns for Diabetes Portfolio Orinase Glimepiride 2 mg Orinase - met 1/2mg Sita Sitagliptin 50/100mg Sita Met Sitagliptin +Metformin 50+500/50+1000mg Gablin Pregablin 75/150mg

41. DIABETESE TREND IN CAMBODIA At a glance 2000 2011 2021 2030 2045 Diabetes estimates (20-79 y) People with diabetes, in 1,000s - 199.4 596 776.2 1,094.60 Age-adjusted comparative prevalence of diabetes, % - 2.9 7.3 8.2 8.6 People with undiagnosed diabetes, in 1,000s - - 334.4 - - Proportion of people with undiagnosed diabetes, % - - 56.1 - -

42. Cambodian Pediatric Symposium would like to inform His Excellency, Professor, Teacher and Physician: The Association will organize a conference on " The 26th Cambodian Pediatrics Symposium)" which will take place on Saturday, 2 Rouch, Bos, Year of the Parchasak, BC. White. 2567 is 27 January 2024 at Sokha Phnom Penh Hotel. To register to participate in “ The 26th Cambodian Pediatric Symposium)”, His Excellency, Professor, Teacher, Physician must register by the QR Code attached or by the Link ) https://forms.gle/cSXvbZPcxH1Z6HYE6 # Can contact 012 456 484 and 017885756 Thank you! 26th Cambodian Pediatrics Symposium

43. Sita Diabetes Club Collaboration with Diabetic Association of Cambodia Top 10 Endocrinologist Intl. CME Provincial Diabetic Association Chapter formation Regional QTR meeting sponsorships

44. Campaigns Cardiac Portfolio Crestat Rosuvastatin 5,10,20 mg Pro Statin Atorvastatin 10/20mg Normozide Losartan Potassium+Hydrochlorothiazide Noclot Clopidogrel 75MG

45. Prevalence of Hypertension in Cambodia 11 percent of adults in Cambodia have Hypertensive , compared with 31 percent in America. But the prevalence is rising much faster in Cambodia than in the US. It has jumped from the fifth most common preventable risk factor for death in 1990 to number two in 2010. HOW Significant is Cardiac Segment

46. History of Cardiac Portfolio 2020 2021 2022 2023 CCL-C00245 - CEF-OD SUSP. 100MG/5ML-30ML-BOT/30ML 8% CCL-C00245 - CEF-OD SUSP. 100MG/5ML-30ML-BOT/30ML 4% CCL-C00245 - CEF-OD SUSP. 100MG/5ML-30ML-BOT/30ML 14% CCL-C00245 - CEF-OD SUSP. 100MG/5ML-30ML-BOT/30ML 10% CCL-D00148 - DILCOZYME SYRUP 120ML-BOT/120ML 4% CCL-E00142 - ESPRA 40MG 14'S-B/14'S 6% CCL-C00246 - CEF-OD SUSP. 200MG/5ML-30ML-BOT/30ML 5% CCL-C00246 - CEF-OD SUSP. 200MG/5ML-30ML-BOT/30ML 4% CCL-E00142 - ESPRA 40MG 14'S-B/14'S 6% CCL-G00166 - GABLIN CAPSULE 75MG 14'S-B/14'S 9% CCL-E00142 - ESPRA 40MG 14'S-B/14'S 4% CCL-E00142 - ESPRA 40MG 14'S-B/14'S 4% CCL-G00166 - GABLIN CAPSULE 75MG 14'S-B/14'S 7% CCL-O00159 - ORINASE 2MG 20'S-B/20'S 3% CCL-G00166 - GABLIN CAPSULE 75MG 14'S-B/14'S 10% CCL-G00166 - GABLIN CAPSULE 75MG 14'S-B/14'S 4% CCL-O005805 - ORINASE MET 2 3X10S-B/3X10'S 8% CCL-O005805 - ORINASE MET 2 3X10S-B/3X10'S 13% CCL-O005805 - ORINASE MET 2 3X10S-B/3X10'S 15% CCL-O005805 - ORINASE MET 2 3X10S-B/3X10'S 20% CCL-S005825 - SITA MET 50-500MG 2X7S-B/2X7'S 3% CCL-S004992 - SITA 50MG TABLET 14S-B/14'S 4% CCL-S005825 - SITA MET 50-500MG 2X7S-B/2X7'S 9% CCL-S004992 - SITA 50MG TABLET 14S-B/14'S 4% CCL-S005826 - SITA MET 50-1000MG 2X7S-B/2X7'S 5% CCL-S005825 - SITA MET 50-500MG 2X7S-B/2X7'S 7% CCL-S005826 - SITA MET 50-1000MG 2X7S-B/2X7'S 6% CCL-S005825 - SITA MET 50-500MG 2X7S-B/2X7'S 14% CCL-V00136 - VITAXON 500MCG 3X10'S-B/30'S 8% CCL-S005826 - SITA MET 50-1000MG 2X7S-B/2X7'S 7% CCL-V00136 - VITAXON 500MCG 3X10'S-B/30'S 6% CCL-S005826 - SITA MET 50-1000MG 2X7S-B/2X7'S 9% CCL-V00137 - VITAXON 500MCG INJ.10AM.-B/10AMP 4% CCL-V00136 - VITAXON 500MCG 3X10'S-B/30'S 6% CCL-V00137 - VITAXON 500MCG INJ.10AM.-B/10AMP 4% CCL-V00136 - VITAXON 500MCG 3X10'S-B/30'S 7% NO CARDIAC PRODUCT Current Status Show HOW MUCH FOCUS IS REQUIRED FOR THIS POTENTIAL SEGMENT

47. Road Map to Penetrate in Cardio Segment - Collaborate with Leading Cardilogist - Sponsorship for International Conference 5 KOLs - PMCT with Key Opinion Leaders with 10 Drs -Sponsorship/ Annual Contract with 20 Drs -Awareness Walk

48. Campaigns for Acute Care Portfolio Prescribers Trade

49. Family Gala in Q2 and Q3 50 Drs with Family GPs involved Acute Care Portfolio and Espra will be targeted

50. Trade Focus Strategy

51. A look at Budget 2023-24